“…In general, the teratogenic potency of a retinoid correlates with its conversion potential to atRA, increasing half‐life/maternal clearance, and its ability to traverse the placenta (Soprano and Soprano,1995; Nau,2001). Teratogenic retinoids must be able to bind RAR, but strength of binding does not correlate well with teratogenic potency (arotinoids are much more potent teratogens than atRA but bind RAR approximately equivalently) (Kistler et al,1990; Bechter et al,1992; Nau,2001). Whereas developing retinoids that have therapeutic value without teratogenicity is problematic, since they would have to bind and activate the RAR, it may be possible to generate retinoids that are unable to be efficiently transferred to the embryo.…”